Harnessing Biomarkers and Algorithms in Assessing the Risk of Malignancy in an Adnexal Mass - The Role of HE4/ROMA in Clinical Cases

Join a 37-minute webinar led by Dr. Kevin Holcomb MD, FACOG, exploring advanced approaches to assessing malignancy risks in adnexal masses. Delve into the critical role of biomarkers and algorithms, particularly focusing on HE4/ROMA in clinical cases. Learn about the evolution beyond traditional CA 125 assays to newer diagnostic tools for improved patient management. Examine how the combination of human epididymis protein 4 (HE4) with CA-125 and the Risk of Ovarian Malignancy Algorithm (ROMA) enhances differentiation between benign and malignant adnexal masses in both pre- and post-menopausal patients. Through two detailed case studies, discover how these diagnostic tools can optimize epithelial ovarian cancer management and influence patient outcomes. Master the application of serum biomarkers for monitoring disease recurrence, understand the emerging significance of HE4 and ROMA in risk assessment, and gain comprehensive insights into utilizing biomarkers and algorithms for patients with adnexal masses.